文献速递血栓与止血

抗PF4阴性血栓形成伴血小板减少综合征中的血小板活化性组蛋白/抗组蛋白IgG复合物

Platelet-activating histone/antihistone IgG complexes in anti-PF4-negative thrombosis and thrombocytopenia syndrome.
PubMed 文献 · Blood Adv · 2025-01-01

描述18例抗PF4/肝素ELISA阴性、与mRNA新冠疫苗接种有时序关系的血栓形成伴血小板减少综合征患者的临床与血清学特征,发现组蛋白/抗组蛋白IgG复合物经FcγRIIa活化血小板,提示TTS新亚型,需进一步研究。

要点

  • 抗PF4阴性TTS患者血清中组蛋白与IgG共沉淀,12份活化血清中8份检出抗组蛋白抗体。
  • 体外生成的组蛋白/抗组蛋白IgG复合物经FcγRIIa强烈活化血小板,单独抗组蛋白IgG无此作用。
  • 114名健康疫苗接种者中2人接种mRNA疫苗后出现抗组蛋白抗体。

核心结论

  • 数据提示存在与血小板活化性组蛋白/抗组蛋白IgG复合物相关的TTS新亚型。
  • 需进一步研究以明确mRNA疫苗接种后抗组蛋白抗体的生物学和临床作用。

研究设计与样本

  • 描述18例抗PF4/肝素ELISA阴性TTS患者的临床与血清学特征,这些患者与mRNA新冠疫苗接种有时序关系。
  • SeCo试验注册于ClinicalTrials.gov,编号NCT04370119。

主要发现

  • 症状始于疫苗接种后中位7天(范围1-61天)。
  • 患者血小板计数59×10^3/μL(范围0-127×10^3/μL),瘀点7例,静脉血栓栓塞11例,动脉血栓6例,弥散性血管内凝血1例,动静脉联合血栓1例。
  • 12份血清诱导FcγRIIa依赖、caspase非依赖的血小板促凝活化,表现为磷脂酰丝氨酸暴露和CD62P表达。
  • 12份血小板活化血清中8份检出抗组蛋白抗体;12份血清中7份检出抗血小板自身抗体,靶向GPIIb/IIIa 5份、GPIb/IX 5份、GPIa/IIa 3份。
  • 含抗GPIIb/IIIa自身抗体的血清也能活化Glanzmann血小板无力症患者血小板,提示这些自身抗体不太可能是血小板活化的原因;114名健康疫苗接种者中2人接种mRNA疫苗后出现抗组蛋白抗体。

关键数值与推荐

  • 体外生成的组蛋白/抗组蛋白IgG复合物经FcγRIIa强烈活化血小板,而单独抗组蛋白IgG不活化血小板。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究以明确mRNA疫苗接种后抗组蛋白抗体的生物学和临床作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombosis and thrombocytopenia syndromes (TTS) describe immune-mediated thrombotic adverse reactions after vaccination against COVID-19. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a well-known subentity of TTS, caused by adenovirus vector-based vaccines. VITT is mediated by anti-platelet factor 4 (PF4) immunoglobulin G (IgG) antibodies, activating platelets via Fc-γ IIa receptors (FcγRIIa). We describe clinical and serological features of 18 patients with anti-PF4/heparin enzyme-linked immunosorbent assay (ELISA)-negative TTS in temporal relationship to messenger RNA (mRNA)-based COVID-19 vaccination. Symptoms began at a median of 7 (range 1 - 61) days after vaccination. Patients showed thrombocytopenia (platelet count 59 × 103/μL; range, 0 to 127 × 103/μL); petechiae (n = 7), venous thromboembolism (n = 11), arterial thrombosis (n = 6), disseminated intravascular coagulation (n = 1), and combined arterial and venous thromboses (n = 1). Twelve sera-induced FcγRIIa-dependent and caspase-independent procoagulant activation of platelets indicated by phosphatidylserine exposure and CD62P expression. We found histones precipitated with IgG fractions of TTS sera. Antibodies binding to histones were found in 8 of 12 platelet-activating sera. Ex vivo-generated histone/antihistone IgG complexes strongly activated platelets via FcγRIIa, whereas antihistone IgG alone did not. Platelet autoantibodies were detected in 7 of 12 sera targeting glycoprotein (GP) IIb/IIIa (n = 5), GPIb/IX (n = 5), and GPIa/IIa (n = 3). However, sera containing platelet anti-GPIIb/IIIa autoantibodies activated also platelets from a patient with Glanzmann thrombasthenia, making it unlikely that these autoantibodies are causative for platelet activation. Finally, 2 of 114 healthy vaccinees developed antihistone antibodies after mRNA-based COVID-19 vaccination. Our data indicate a new subentity of TTS associated with platelet-activating histone/antihistone IgG complexes. Further studies are warranted to characterize the biological and clinical role of post-mRNA-based vaccination antihistone antibodies. The SeCo trial was registered at www.ClinicalTrials.gov as #NCT04370119.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Esefeld M, Handtke S, Kaiser R, et al. Platelet-activating histone/antihistone IgG complexes in anti-PF4-negative thrombosis and thrombocytopenia syndrome. Blood Adv. 2025. PMID: 40179418. doi:10.1182/bloodadvances.2024015076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。